Apyx Medical Corporation Reports First Quarter 2026 Financial Results
Rhea-AI Summary
Apyx Medical (NASDAQ:APYX) reported Q1 2026 total revenue of $12.5 million, up 32.4% year-over-year, driven by a 36.1% increase in Surgical Aesthetics to $10.7 million. Net loss attributable to stockholders narrowed to $2.1 million (‑$0.05/share). Adjusted EBITDA loss improved to $0.3 million. Cash and cash equivalents were $31.1 million as of March 31, 2026. Management raised 2026 total revenue guidance to $59.0–$60.0 million and increased Surgical Aesthetics guidance to $54.0–$55.0 million. Apyx cited stronger international sales, including South Korea, and AYON adoption as drivers.
Positive
- Total revenue +32.4% to $12.5M in Q1 2026
- Surgical Aesthetics revenue +36.1% to $10.7M
- Raised FY2026 revenue guidance to $59.0–$60.0M
- Adjusted EBITDA loss improved to $0.3M
- Cash and cash equivalents of $31.1M at March 31, 2026
Negative
- Net loss attributable to stockholders of $2.1M in Q1 2026
- OEM revenue trend expected to decline over the year
- Operating expenses near $8.8M in Q1, with annual expectation < $45.0M
News Market Reaction – APYX
In the May 7 session, APYX gained 21.92%, reflecting a significant positive market reaction. Argus tracked a peak move of +8.6% during that session. Argus tracked a trough of -7.4% from its starting point during tracking. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility. Trading volume was elevated at 2.1x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 10 | Q4/FY25 earnings | Positive | +0.6% | Q4 and FY2025 revenue growth with positive Q4 adjusted EBITDA and 2026 guidance. |
| Nov 06 | Q3 2025 earnings | Positive | +6.7% | Q3 revenue growth, improved gross margin, narrowed net loss, AYON US launch. |
| Aug 07 | Q2 2025 earnings | Positive | +11.2% | Q2 results with improved losses and raised FY2025 revenue guidance on AYON strength. |
| May 08 | Q1 2025 earnings | Negative | -5.6% | Q1 revenue decline and OEM weakness, partly offset by improved net loss. |
| Mar 13 | Q4/FY24 earnings | Negative | -2.8% | Mixed Q4 performance with OEM declines and ongoing losses despite cost savings. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings releases have generally prompted positive price reactions, especially when tied to AYON expansion and raised revenue guidance.
Across recent earnings reports, Apyx has emphasized growth in Surgical Aesthetics and the AYON platform, with multiple quarters showing improved adjusted EBITDA and narrowed net losses. Prior updates on Q3 and Q4 2025 included revenue growth, guidance raises to as high as $52.5M, and launches or regulatory progress for AYON. Today’s Q1 2026 results continue that pattern with higher revenue, better margins, and an increased full‑year 2026 outlook.
Key Terms
adjusted EBITDA financial
non-GAAP financial measure financial
operating lease right-of-use assets financial
finance lease right-of-use assets financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Reported total revenue of
$12.5 million in the first quarter of 2026 primarily driven by36% growth in the Surgical Aesthetics segment - Raised total revenue guidance for FY2026 to a range of
$59.0 million to$60.0 million - Management to host a conference call today at 8:00 a.m. ET
CLEARWATER, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported financial results for its first quarter ended March 31, 2026.
Recent Financial and Operating Highlights:
- Reported total revenue of
$12.5 million in the first quarter of 2026, compared with$9.4 million in the same period last year.- Surgical Aesthetics revenue increased to
$10.7 million in the first quarter of 2026, compared with$7.9 million in the first quarter of 2025, which was the result of domestic sales of AYON, Renuvion generators internationally, and single use handpieces worldwide. - OEM revenue was approximately
$1.8 million in the first quarter of 2026, representing an increase of13.8% from the same period last year.
- Surgical Aesthetics revenue increased to
- Net loss attributable to stockholders of
$2.1 million in the first quarter of 2026, compared with a net loss attributable to stockholders of$4.2 million in the first quarter of 2025. - Adjusted EBITDA loss was
$0.3 million for the first quarter of 2026, compared with an Adjusted EBITDA loss of$2.4 million for the first quarter of 2025. - International sales exceeded expectations, driven in part by sales of the Apyx One Console and single‑use handpieces in South Korea following regulatory approval in December 2025. South Korea represents an attractive growth market, with the cosmetic surgery market estimated at
$1.7 billion in 2024 and projected to exceed$3.9 billion by 2031. - Renuvion won the 2026 NewBeauty award for “Best Minimally Invasive Skin Tightener” for the second year in a row.
“Our first quarter results reflect continued execution against our commercial strategy, with strong revenue growth driven by adoption of AYON in the U.S., increasing demand for Renuvion internationally and an increase in handpieces worldwide,” said Charlie Goodwin, President and Chief Executive Officer. “During the quarter, our team delivered on several fronts, including growing Surgical Aesthetic sales including expansion of AYON and exceeding expectations in key international markets such as South Korea. Taken together, this performance reinforces our confidence in the business and supports our decision to raise our revenue outlook for the full year 2026.”
The following tables present revenue by reportable segment and geography:
| Three Months Ended | |||||||||||||
| March 31, | |||||||||||||
| (In thousands) | 2026 | 2025 | $ Change | % Change | |||||||||
| Surgical Aesthetics | $ | 10,734 | $ | 7,887 | $ | 2,847 | 36.1 | % | |||||
| OEM | 1,756 | 1,543 | 213 | 13.8 | % | ||||||||
| Total | $ | 12,490 | $ | 9,430 | $ | 3,060 | 32.4 | % | |||||
| Three Months Ended | |||||||||||||||||
| March 31, | |||||||||||||||||
| (In thousands) | 2026 | 2025 | $ Change | % Change | |||||||||||||
| Domestic | $ | 8,112 | $ | 6,743 | $ | 1,369 | 20.3 | % | |||||||||
| International | 4,378 | 2,687 | 1,691 | 62.9 | % | ||||||||||||
| Total | $ | 12,490 | $ | 9,430 | $ | 3,060 | 32.4 | % | |||||||||
First Quarter 2026 Results:
Total revenue for the three months ended March 31, 2026 increased to
Gross profit for the three months ended March 31, 2026, increased to
Operating expenses were essentially flat at
Other expense, net was relatively flat at
Net loss attributable to stockholders was
Adjusted EBITDA loss for the three months ended March 31, 2026 was
As of March 31, 2026, the Company had cash and cash equivalents of
Financial Guidance for Full Year 2026:
The Company announced an upward revision to select financial guidance targets for the year ending December 31, 2026:
- Total revenue in the range of
$59.0 million to$60.0 million , up from the previous guidance of$57.5 million to$58.5 million . This is compared with$52.8 million reported for the year ended December 31, 2025.- Total revenue guidance assumes:
- Surgical Aesthetics revenue is expected to be in the range of
$54.0 million to$55.0 million , up from the previous guidance of$53.0 million to$54.0 million . This is compared with approximately$45.3 million reported for the year ended December 31, 2025. - OEM revenue is expected to be approximately
$5.0 million , up from$4.5 million . This is compared with approximately$7.5 million for the year ended December 31, 2025.
- Surgical Aesthetics revenue is expected to be in the range of
- Total revenue guidance assumes:
- The Company continues to expect operating expenses of less than
$45.0 million for the year ended December 31, 2026.
Conference Call Details:
Management will host a conference call at 8:00 a.m. Eastern Time today, May 7th, to discuss the results of the first quarter ended March 31, 2026, followed by a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international callers) and provide access code 81537. Participants should ask for the “Apyx Medical Corporation Call”. A live webcast of the call will be accessible via the following link: Apyx Medical Earnings Webcast and via the Investor Relations section of the Company’s website, where it will also be archived for future reference.
An archive of the webcast will be accessible approximately one hour after the live event ends on the Investor Relations section of the Company’s website (click here).
Investor Relations Contact:
Jeremy Feffer, Managing Director, LifeSci Advisors
OP: 212-915-2568
jfeffer@lifesciadvisors.com
About AYON Body Contouring System™:
AYON is a groundbreaking, surgeon-designed body contouring system that combines precision, versatility, and innovation in an all-in-one platform. It seamlessly integrates advanced fat removal technologies, Renuvion’s tissue contraction and electrosurgical capabilities, empowering surgeons to deliver the most comprehensive body contouring treatments for patients. With advanced features like LIFT Technology for real-time adjustments and Renuvion for enhanced tissue contraction, AYON sets a new standard in surgical care, streamlining procedures and maximizing patient outcomes. Backed by Apyx Medical’s expertise and evidence-based design, AYON delivers consistent, reliable performance and an unmatched return on investment. As the first of its kind, AYON is revolutionizing body contouring and shaping the future of aesthetic surgery.
About Apyx Medical Corporation:
Apyx Medical Corporation is a surgical aesthetics company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion® and the AYON Body Contouring System™ in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical documents. The AYON Body Contouring System is an FDA-cleared, groundbreaking, surgeon-designed body contouring system that combines precision, versatility, and innovation in an all-in-one platform. It seamlessly integrates fat removal, closed loop contouring, electrosurgical capabilities and Renuvion for tissue contraction, empowering surgeons to deliver the most comprehensive body contouring treatments for patients. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.
Cautionary Statement on Forward-Looking Statements:
Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.
All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including but not limited to, projections of net revenue, margins, expenses, net earnings, net earnings per share, or other financial items; projections or assumptions concerning the possible receipt by the Company of any regulatory approvals from any government agency or instrumentality including but not limited to the U.S. Food and Drug Administration (the “FDA”), supply chain disruptions, component shortages, manufacturing disruptions or logistics challenges; or macroeconomic or geopolitical matters and the impact of those matters on the Company’s financial performance.
Forward-looking statements and information are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause the Company’s actual results to differ materially and that could impact the Company and the statements contained in this release include but are not limited to risks, uncertainties and assumptions relating to the regulatory environment in which the Company is subject to, including the Company’s ability to gain requisite approvals for its products from the FDA and other governmental and regulatory bodies, both domestically and internationally; sudden or extreme volatility in commodity prices and availability, including supply chain disruptions; changes in general economic, business or demographic conditions or trends; changes in and effects of the geopolitical environment; liabilities and costs which the Company may incur from pending or threatened litigations, claims, disputes or investigations; and other risks that are described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and the Company’s other filings with the Securities and Exchange Commission. For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.
| APYX MEDICAL CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (In thousands, except per share data) | |||||||||
| Three Months Ended | |||||||||
| March 31, | |||||||||
| 2026 | 2025 | ||||||||
| Sales, net | $ | 12,490 | $ | 9,430 | |||||
| Cost of sales | 4,565 | 3,765 | |||||||
| Gross profit | 7,925 | 5,665 | |||||||
| Other costs and expenses: | |||||||||
| Research and development | 765 | 804 | |||||||
| Professional services | 1,242 | 1,365 | |||||||
| Salaries and related costs | 3,253 | 3,081 | |||||||
| Selling, general and administrative | 3,576 | 3,466 | |||||||
| Total other costs and expenses | 8,836 | 8,716 | |||||||
| Loss from operations | (911 | ) | (3,051 | ) | |||||
| Interest income | 244 | 304 | |||||||
| Interest expense | (1,369 | ) | (1,376 | ) | |||||
| Other income, net | 36 | — | |||||||
| Total other expense, net | (1,089 | ) | (1,072 | ) | |||||
| Loss before income taxes | (2,000 | ) | (4,123 | ) | |||||
| Income tax expense | 143 | 49 | |||||||
| Net loss | (2,143 | ) | (4,172 | ) | |||||
| Net loss attributable to non-controlling interest | (35 | ) | (22 | ) | |||||
| Net loss attributable to stockholders | $ | (2,108 | ) | $ | (4,150 | ) | |||
| Loss per share: | |||||||||
| Basic and diluted | $ | (0.05 | ) | $ | (0.10 | ) | |||
| APYX MEDICAL CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share data) | |||||||||
| March 31, 2026 | |||||||||
| (Unaudited) | December 31, 2025 | ||||||||
| ASSETS | |||||||||
| Current assets: | |||||||||
| Cash and cash equivalents | $ | 31,137 | $ | 31,740 | |||||
| Trade accounts receivable, net of allowance of | 12,755 | 16,776 | |||||||
| Inventories, net of provision for obsolescence of | 9,536 | 8,602 | |||||||
| Prepaid expenses and other current assets | 1,367 | 1,353 | |||||||
| Total current assets | 54,795 | 58,471 | |||||||
| Property and equipment, net of accumulated depreciation and amortization of | 2,235 | 2,371 | |||||||
| Operating lease right-of-use assets | 4,092 | 4,218 | |||||||
| Finance lease right-of-use assets | 22 | 28 | |||||||
| Other assets | 1,881 | 1,752 | |||||||
| Total assets | $ | 63,025 | $ | 66,840 | |||||
| LIABILITIES AND EQUITY | |||||||||
| Current liabilities: | |||||||||
| Accounts payable | $ | 2,629 | $ | 3,058 | |||||
| Accrued expenses and other current liabilities | 6,377 | 8,214 | |||||||
| Current portion of operating lease liabilities | 420 | 407 | |||||||
| Current portion of finance lease liabilities | 21 | 21 | |||||||
| Total current liabilities | 9,447 | 11,700 | |||||||
| Long-term debt, net of debt discounts and issuance costs | 35,087 | 34,849 | |||||||
| Long-term operating lease liabilities | 3,926 | 4,051 | |||||||
| Long-term finance lease liabilities | 7 | 12 | |||||||
| Long-term contract liabilities | 1,131 | 1,050 | |||||||
| Other liabilities | 339 | 347 | |||||||
| Total liabilities | 49,937 | 52,009 | |||||||
| EQUITY | |||||||||
| Preferred stock, | — | — | |||||||
| Common stock, | 42 | 42 | |||||||
| Additional paid-in capital | 104,020 | 103,620 | |||||||
| Accumulated deficit | (91,230 | ) | (89,122 | ) | |||||
| Total stockholders’equity | 12,832 | 14,540 | |||||||
| Non-controlling interest | 256 | 291 | |||||||
| Total equity | 13,088 | 14,831 | |||||||
| Total liabilities and equity | $ | 63,025 | $ | 66,840 | |||||
Use of Non-GAAP Financial Measure:
The Company has presented the following non-GAAP financial measure in this press release: adjusted EBITDA. The Company defines adjusted EBITDA as its reported net loss attributable to stockholders (GAAP) plus income tax expense (benefit), interest income and expense, depreciation and amortization, stock-based compensation expense and other significant non-recurring items.
We present the following non-GAAP measure of adjusted EBITDA because we believe such measure is a useful indicator of our operating performance. Our management uses adjusted EBITDA principally as a measure of our operating performance and believes that this measure is useful to investors because it is frequently used by analysts, investors and other interested parties to evaluate companies in our industry. We also believe that this measure is useful to our management and investors as a measure of comparative operating performance from period to period. The non-GAAP financial measure presented in this release should not be considered as a substitute for, or preferable to, the measures of financial performance prepared in accordance with GAAP.
| APYX MEDICAL CORPORATION RECONCILIATION OF GAAP NET LOSS TO NON-GAAP ADJUSTED EBITDA (Unaudited) | |||||||||
| Three Months Ended | |||||||||
| (In thousands) | March 31, | ||||||||
| 2026 | 2025 | ||||||||
| Net loss attributable to stockholders | $ | (2,108 | ) | $ | (4,150 | ) | |||
| Interest income | (244 | ) | (304 | ) | |||||
| Interest expense | 1,369 | 1,376 | |||||||
| Income tax expense | 143 | 49 | |||||||
| Depreciation and amortization | 202 | 138 | |||||||
| Stock-based compensation | 312 | 451 | |||||||
| Adjusted EBITDA | $ | (326 | ) | $ | (2,440 | ) | |||
